%20(dragged)-1752956736212.webp&w=3840&q=75)
2025 NOSCM | Early Stages Colon Cancer- Use of Biomarkers To Decide Therapy (From MSI to ctDNA)
Overview
Dr. Mike Cusnir discussed biomarkers in early-stage colon cancer. MSI-high patients fare better. The ATomic trial showed 80% 3-year survival with immunotherapy + FOLFOX. Neoadjuvant immunotherapy yielded high response rates. MRD testing, ctDNA monitoring, and aspirin for PIK3CA mutations aid treatment.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Mike Cusnir, MD
Date of Release
July 20th, 2025
-1755988787553.webp&w=3840&q=75)
-1755988610269.webp&w=3840&q=75)